Hydroxyapatite — Drug Target

All drugs that target Hydroxyapatite — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bisphosphonate

Phase 3 pipeline (4)

• Zoledronic acid i.v. 2 years · Ludwig-Maximilians - University of Munich · Bisphosphonate · Oncology, Bone Diseases
  Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.
• Placebo to Alendronate · Amgen · Bisphosphonate · Osteoporosis
  Alendronate works by inhibiting osteoclast-mediated bone resorption.
• Zoledronic acid i.v. 5 years · Ludwig-Maximilians - University of Munich · Bisphosphonate · Oncology, Bone Diseases
  Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.
• risedronate combine · Hanlim Pharm. Co., Ltd. · Bisphosphonate · Osteoporosis
  Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts.